Medical Oncology最新文献_第9页

Molecular mechanism of genetic, epigenetic, and metabolic alteration in lung cancer.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-02-02 DOI: 10.1007/s12032-025-02608-5

Sheeri Fatima, Vineet Kumar, Dhruv Kumar

引用次数: 0

Integrative pan-cancer genomic analysis highlights mitochondrial protein p32 as a potential therapeutic target in Myc-driven tumorigenesis.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-02-01 DOI: 10.1007/s12032-025-02604-9

Qiufen Bi, Jun Nie, Qiang Wu, Liang Sun, Shuang Zhu, Jin Bai, Yong Liu, Fang Huang, Keli Chai

{"title":"Integrative pan-cancer genomic analysis highlights mitochondrial protein p32 as a potential therapeutic target in Myc-driven tumorigenesis.","authors":"Qiufen Bi, Jun Nie, Qiang Wu, Liang Sun, Shuang Zhu, Jin Bai, Yong Liu, Fang Huang, Keli Chai","doi":"10.1007/s12032-025-02604-9","DOIUrl":"10.1007/s12032-025-02604-9","url":null,"abstract":"Tumor metabolic reprogramming, particularly involving mitochondrial metabolism, is a hallmark of malignancy. The mitochondrial protein p32 (C1QBP) has emerged as a critical regulator in various cancers, frequently associated with poor patient prognosis. However, the role of p32 across different cancer types remains largely unexplored. Our bioinformatics analysis demonstrates that p32 is significantly overexpressed in several malignancies and is closely involved in multiple oncogenic pathways related to tumor progression and metabolic reprogramming. Moreover, p32 expression positively correlates with genomic heterogeneity and drug sensitivity. We identified a strong association between p32 and c-Myc in both normal and cancerous tissues. We confirmed that p32 is a direct transcriptional target of c-Myc, which upregulates p32 by binding to its promoter. Functional experiments established that p32 is crucial for MYC-driven tumorigenesis, with its knockdown or knockout inhibiting tumor proliferation and extending survival. Targeting p32 may inhibit MYC-driven tumorigenesis, highlighting its potential as a therapeutic target in MYC-driven cancers.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 3","pages":"60"},"PeriodicalIF":2.8,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143075003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epstein-Barr virus-infected nasopharyngeal carcinoma therapeutics: oncoprotein targets and clinical implications.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-31 DOI: 10.1007/s12032-025-02610-x

Jacqueline Kar Kei Mark, Aik-Hong Teh, Beow Keat Yap

{"title":"Epstein-Barr virus-infected nasopharyngeal carcinoma therapeutics: oncoprotein targets and clinical implications.","authors":"Jacqueline Kar Kei Mark, Aik-Hong Teh, Beow Keat Yap","doi":"10.1007/s12032-025-02610-x","DOIUrl":"10.1007/s12032-025-02610-x","url":null,"abstract":"Nasopharyngeal carcinoma (NPC) is a distinctive epithelial cancer closely associated with Epstein-Barr Virus (EBV) infection, posing significant challenges in diagnosis and treatment due to its resistance to conventional therapies and high recurrence rates. Current therapies, including radiotherapy and chemotherapy, exhibit limited efficacy, particularly in recurrent or metastatic cases, highlighting the urgent need for novel therapeutic strategies. Targeting EBV oncoproteins, such as Epstein-Barr Virus encoded Nuclear Antigen 1 (EBNA1), Latent Membrane Protein 1 (LMP1), and Latent Membrane Protein 2 (LMP2), presents a promising therapeutic avenue in NPC treatment. This review discusses the latest advancements in drug discovery targeting EBV oncoproteins, emphasizing the identification of inhibitors for specific functional regions of oncoproteins EBNA1, LMP1, and LMP2. Particular attention is given to the molecular mechanisms of these inhibitors and their preclinical or clinical potential in treating EBV-positive NPC. These developments highlight a promising future for targeted therapies in improving outcomes for NPC patients.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 3","pages":"59"},"PeriodicalIF":2.8,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A comprehensive insights of cancer immunotherapy resistance.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-30 DOI: 10.1007/s12032-025-02605-8

Laavanya Das, Subhadip Das

引用次数: 0

Natural compounds as modulators of miRNAs: a new frontier in bladder cancer treatment.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-30 DOI: 10.1007/s12032-025-02613-8

Ahmed I Abulsoud, Shaza H Aly, Sherif S Abdel Mageed, Nourhan M Abdelmaksoud, Walaa A El-Dakroury, Osama A Mohammed, Mustafa Ahmed Abdel-Reheim, Mohamed Bakr Zaki, Nehal I Rizk, Manar Mohammed El Tabaa, Mahmoud Rashed, Riham A El-Shiekh, Ahmed S Doghish

{"title":"Natural compounds as modulators of miRNAs: a new frontier in bladder cancer treatment.","authors":"Ahmed I Abulsoud, Shaza H Aly, Sherif S Abdel Mageed, Nourhan M Abdelmaksoud, Walaa A El-Dakroury, Osama A Mohammed, Mustafa Ahmed Abdel-Reheim, Mohamed Bakr Zaki, Nehal I Rizk, Manar Mohammed El Tabaa, Mahmoud Rashed, Riham A El-Shiekh, Ahmed S Doghish","doi":"10.1007/s12032-025-02613-8","DOIUrl":"10.1007/s12032-025-02613-8","url":null,"abstract":"Bladder cancer (BC) is a major global health issue with a high recurrence rate and limited effective treatments. Over the past few years, it has become evident that miRNAs play a role in the carcinogenesis process, particularly in regulating genes that promote cancer cell proliferation and invasion. This review focuses on the extent to which natural products can act as potential miRNA modulators for the management of bladder cancer. Polyphenols, flavonoids, and other phytochemicals are natural compounds found to have inherent potential to modulate miRNAs and reform the oncogenic properties of bladder cancer cells regulating cell growth and death. In integration with the current cancer treatment regimes, such natural agents may safely substitute for the traditional chemical chemotherapeutic agents of the conventional approaches. To this end, this review presents the existing knowledge of natural compounds as regulators of miRNA, their mechanisms for the management of BC, the role of their nanoparticles, and future novel therapies. The use of these compounds is not only a therapeutic practice for the conditions of bladder cancer, but it also upholds new avenues for creativity.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 3","pages":"56"},"PeriodicalIF":2.8,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Roles of anoikis in hepatocellular carcinoma: mechanisms and therapeutic potential.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-30 DOI: 10.1007/s12032-025-02612-9

Chen Chen, Mengyao Wang, Daoyuan Tu, Jun Cao, Chi Zhang, Dousheng Bai

{"title":"Roles of anoikis in hepatocellular carcinoma: mechanisms and therapeutic potential.","authors":"Chen Chen, Mengyao Wang, Daoyuan Tu, Jun Cao, Chi Zhang, Dousheng Bai","doi":"10.1007/s12032-025-02612-9","DOIUrl":"10.1007/s12032-025-02612-9","url":null,"abstract":"Hepatocellular carcinoma (HCC), the most common primary liver cancer, is a highly aggressive malignancy with limited viable therapeutic options. For early HCC, resection surgery is currently the most effective treatment. However, in advanced stages, resection alone does not sufficiently address the disease, so finding a method with a better prognosis is necessary. Anoikis, known as matrix detachment-induced apoptosis or detachment-induced cell death, is crucial for tissue development and homeostasis. Cancer cells develop means to evade anoikis, e.g. anoikis resistance, thereby allowing for cells to survive under anchorage-independent conditions. HCC cells often acquire resistance to anoikis, allowing them to survive after detaching from the extracellular matrix and contributing to tumor spread. This review discusses the mechanisms of anoikis in HCC, exploring the potential of drug-induced anoikis and targeting anoikis resistance as promising therapeutic strategies for treating HCC, analyzing the value of anoikis in the immune of HCC, and propose potential pathways in oncotherapy, which can provide background knowledge for subsequent related research.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 3","pages":"58"},"PeriodicalIF":2.8,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143066413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research progress on N6-methyladenosine RNA modification in osteosarcoma: functions, mechanisms, and potential clinical applications.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-24 DOI: 10.1007/s12032-024-02597-x

Ying Yang, Wen-Juan Ni, Yadong Yang, Junnan Liao, Yuqian Yang, Jianwei Li, Xiuzhi Zhu, Chun Guo, Fuhua Xie, Xiao-Min Leng

{"title":"Research progress on N6-methyladenosine RNA modification in osteosarcoma: functions, mechanisms, and potential clinical applications.","authors":"Ying Yang, Wen-Juan Ni, Yadong Yang, Junnan Liao, Yuqian Yang, Jianwei Li, Xiuzhi Zhu, Chun Guo, Fuhua Xie, Xiao-Min Leng","doi":"10.1007/s12032-024-02597-x","DOIUrl":"10.1007/s12032-024-02597-x","url":null,"abstract":"Osteosarcoma (OS) is the most commonly diagnosed primary malignant bone tumor in children and adolescents. Despite significant advancements in therapeutic strategies against OS over the past few decades, the prognosis for this disease remains poor, largely due to its high invasiveness and challenges associated with its treatment. N6-methyladenosine (m6A) modification is one of the most abundant epigenetic modifications of RNAs, and many studies have highlighted its crucial role in OS. This article provides a comprehensive summary and introduction to m6A regulators, including methyltransferases, demethylases, and binding proteins. The article emphasizes how regulated m6A modifications can either promote or inhibit OS. It also delves into the mechanisms by which m6A-modified messenger RNAs (mRNAs) and noncoding RNAs (ncRNAs) participate in signaling pathways such as the Wnt/β-catenin, PI3K/AKT, and STAT3 pathways, and discusses these mechanisms in detail. Given the abnormal expression of m6A regulators in OS, the article also explores their potential applications as biomarkers or therapeutic targets in clinical settings. It is anticipated that this review will provide new insights into the diagnosis and treatment of OS.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 3","pages":"55"},"PeriodicalIF":2.8,"publicationDate":"2025-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143033440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ameliorative effect of aqueous leaf extract of Pistacia lentiscus L. against oxaliplatin-induced hepatic injury, oxidative stress, and DNA damage in vitro and in vivo.

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-22 DOI: 10.1007/s12032-025-02599-3

Nesrine Chouikh, Lamia Benguedouar, Hanen Chaabani, Salwa Abid Essefi, Zohra Haouas, Meriem Mehdi, Sihem Safta Skhiri, Mohamed Sifour

{"title":"Ameliorative effect of aqueous leaf extract of Pistacia lentiscus L. against oxaliplatin-induced hepatic injury, oxidative stress, and DNA damage in vitro and in vivo.","authors":"Nesrine Chouikh, Lamia Benguedouar, Hanen Chaabani, Salwa Abid Essefi, Zohra Haouas, Meriem Mehdi, Sihem Safta Skhiri, Mohamed Sifour","doi":"10.1007/s12032-025-02599-3","DOIUrl":"10.1007/s12032-025-02599-3","url":null,"abstract":"The current study aimed to assess the preventive effects of aqueous leaf extract of Pistacia lentiscus (ALEPL) against Oxaliplatin (OXA)-induced DNA damage, hepatic injury, and oxidative stress. The in vitro cytotoxic and genotoxic effects of OXA and ALEPL on HCT116 colon cancer cells were evaluated using the MTT (Tetrazolium salt reduction) assay and comet assay. The in vivo study involved 24 female NMRI (Naval Medical Research Institute) mice that were equally divided into four groups as follows: Control group, ALEPL-treated group (100 mg/kg), OXA-treated group (7 mg/kg), and ALEPL-treated group (100mg/kg) + OXA (7mg/kg). All animals were sacrificed 48 h after OXA treatment. Samples of liver and blood were collected for histopathological, micronucleus, and biochemical analyses. Oxidative stress parameters were also evaluated through non-enzymatic and enzymatic antioxidant activities. Our findings demonstrated that ALEPL contains high phenolic compounds. In the MTT assay, OXA exerted the most potent cytotoxic effect, but ALEPL alone showed no toxic effect in HCT116 cells. Furthermore, OXA administration caused significant DNA fragmentation both in vitro and in vivo, elevated serum biochemical parameters, and confirmed acute liver damage through histopathological observations compared to the control group. OXA exposure also led to a decrease in hepatic glutathione (GSH) and an increase in lipid peroxidation and antioxidant enzyme activities. From the results of our study, ALEPL pretreatment significantly restored the hepatic toxicity and DNA damage as well as the oxidative stress profile induced by OXA.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 2","pages":"54"},"PeriodicalIF":2.8,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143024068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enhanced antitumor efficacy of nanostructured lipid carrier co-loaded with docetaxel and 5-fluorouracil for targeted gastric cancer therapy. 纳米结构脂质载体与多西紫杉醇和5-氟尿嘧啶共载增强胃癌靶向治疗的抗肿瘤效果。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-22 DOI: 10.1007/s12032-025-02603-w

Hanan Alyami, Sitah Alharthi, Ali Jaber Alqahtani, Hasan Ebrahimi Shahmabadi, Seyed Ebrahim Alavi

{"title":"Enhanced antitumor efficacy of nanostructured lipid carrier co-loaded with docetaxel and 5-fluorouracil for targeted gastric cancer therapy.","authors":"Hanan Alyami, Sitah Alharthi, Ali Jaber Alqahtani, Hasan Ebrahimi Shahmabadi, Seyed Ebrahim Alavi","doi":"10.1007/s12032-025-02603-w","DOIUrl":"10.1007/s12032-025-02603-w","url":null,"abstract":"This study presents nanostructured lipid carrier (NLC) co-loaded with Docetaxel (DCT) and 5-Fluorouracil (5-FU) as a targeted therapeutic approach for gastric cancer (GC). Using nanoprecipitation, NLC-DCT/5-FU were synthesized and exhibited an average particle size of 215.3 ± 10.4 nm, a polydispersity index (PDI) of 0.29, and a zeta potential of - 17.1 mV. Encapsulation efficiency reached 95.9% for DCT and 5-FU, with a loading efficiency of 11.2%. In vitro release studies demonstrated a biphasic release profile, with an initial burst and sustained release, achieving 85.6% DCT and 75.8% 5-FU release over 72 h. Cytotoxicity assays in MKN45 cells showed a significantly lower half-maximal inhibitory concentration (IC50) for NLC-DCT/5-FU (0.3 µM) compared to free DCT (3.9 µM) and free 5-FU (19.5 µM), indicating enhanced efficacy. In vivo evaluation in a GC mouse model confirmed substantial tumor volume reduction to 213 mm3 with NLC-DCT/5-FU treatment, compared to 432 mm3 with the free-drug combination. Systemic safety assessment showed minimal adverse effects, suggesting the nanoparticles' enhanced therapeutic index. These results demonstrate that NLC-based co-delivery systems could substantially improve the clinical outcomes of GC therapy.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":"42 2","pages":"53"},"PeriodicalIF":2.8,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fusion of tumor cells and mesenchymal stem/stroma cells: a source of tumor heterogeneity, evolution and recurrence. 肿瘤细胞与间充质干细胞/间质细胞的融合：肿瘤异质性、进化和复发的来源。

IF 2.8 4区医学

Medical Oncology Pub Date : 2025-01-21 DOI: 10.1007/s12032-024-02595-z

Zhen Liu, Yihao Wang, Zesheng Peng, Hui Li, Haofei Wang, Yuyi Wu, Xiaobing Jiang, Peng Fu

引用次数: 0